Mycofoli 180 Tablet contains Mycophenolate Sodium 180 mg, a selective immunosuppressant widely prescribed in organ transplant medicine to prevent graft rejection.
This tablet works by inhibiting inosine monophosphate dehydrogenase (IMPDH), leading to suppression of T- and B-lymphocyte proliferation, thereby reducing immune-mediated damage to transplanted organs. It is particularly suitable for patients requiring lower-dose or stepwise immunosuppression under specialist supervision.
Clinically, Mycofoli 180 Tablet is used in renal, hepatic, and cardiac transplant protocols, often as part of combination immunosuppressive therapy to maintain graft function and reduce rejection risk.
The tablet provides accurate dosing, consistent bioavailability, and dependable therapeutic outcomes, making it ideal for hospitals, transplant centers, specialty clinics, and pharmacies managing long-term post-transplant immunosuppressive care.
Common side effects may include nausea, diarrhea, abdominal discomfort, headache, and increased risk of infections. Rare but serious adverse effects include leukopenia, anemia, thrombocytopenia, severe infections, and hypersensitivity reactions.
Mycofoli 180 Tablet is indicated for the prevention of organ transplant rejection in renal, cardiac, or hepatic transplant recipients. It may also be used for the management of certain autoimmune disorders under specialist supervision.
Use Mycofoli 180 Tablet strictly under medical supervision. Regular monitoring of complete blood count, liver and kidney function, and infection status is essential. Inform your doctor if you have active infections, bone marrow suppression, or are taking other immunosuppressive medicines. Avoid live vaccines during therapy and seek immediate medical attention if fever, unusual bleeding, or signs of infection occur.
Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children. Do not use beyond the expiry date.